

PA Description	Umeclidinium Inhaled (Incruse Ellipta)
Managed by	Managed Care Organizations (MCOs) contracted by the Puerto Rico Health Insurance Administration (known in Spanish as <i>Administración de Seguros de Salud</i> or ASES) to provide pharmacy services to the insured of the Government Health Plan.
Covered Uses	a) Chronic Obstructive Pulmonary Disease (COPD) (ICD-10: J44.9)
Exclusion Criteria	a) None
Required Medical Information	a) Physician must document on the prescription prior use of inhaled ipratropium, either alone or in combination
Age Restriction	a) Patients over eighteen (18) years of age
Prescriber Restriction	a) None
Coverage Duration	a) Twelve (12) months
Other Criteria	a) Dose to be approved: one blister strip for inhalation once a day; supply for 30 days